Skip to main content
. Author manuscript; available in PMC: 2020 Sep 12.
Published in final edited form as: J Hypertens. 2020 Aug;38(8):1443–1456. doi: 10.1097/HJH.0000000000002438

Table 1.

Signs and symptoms in patients with and without PPGL enrolled in the full study cohort (N=2017) and three different patient sub-populations according to their clinical presentation§

  All patients Signs & symptoms Incidentaloma Surveillance

  PPGL No PPGL PPGL No PPGL PPGL No PPGL PPGL No PPGL

N 243 1774 89 1170 88 387 66 217
BMI (kg/m2) 25* 28 25* 28 25* 29 25* 27
Heart rate (b/min) 79* 72 81* 72 78* 73 77* 70
Pallor (%) 26* 13 37* 15 21* 10 18* 7
Sweating (%) 46* 28 55* 30 47* 25 32* 21
Palpitations (%) 46* 36 65* 44 46* 22 21 19
Tremor (%) 25* 15 33* 18 21* 8 18* 6
Nausea /vomiting (%) 21* 11 26* 12 18 11 20* 10
Symptom score ≥3** 42 18 56 21 40 13 28 1
Hypertension (%) 83 85 95 93 80 78 71 58
Headaches (%) 38 39 46 45 39 29 27 25
Weakness (%) 42* 35 51* 36 34 32 42 32
Panic/anxiety (%) 25 25 37 32 19 14 15* 7
Flushing (%) 20 23 21 27 23 17 14 14
Constipation (%) 14* 9 17* 9 10 9 14 7
§

The full study cohort of the PMT study (Prospective Monoamine-Producing Tumor study)y (modified from [18]).

PPGL, Phaeochromocytoma or paraganglioma

*

significant differences between patients with and without PPGL;

**

symptom score: one point for each sign: BMI < 25 kg/m2, heart rate ≥85 beats/min, pallor, sweating, palpitations, tremor and nausea; a negative point for obesity;